NTLA - Intellia Therapeutics Inc Forecast, Target Price
This page provides a detailed financial overview and forecast for Intellia Therapeutics Inc (NTLA). It includes key financial metrics, stock performance data, analyst recommendations, and insider transaction information. The company's current stock price, market capitalization, earnings, sales figures, and short interest are all presented.
NTLA - Intellia Therapeutics Inc Options
This article provides a detailed financial overview and key statistics for Intellia Therapeutics Inc (NTLA). It covers various financial metrics, performance indicators, insider ownership, institutional ownership, and valuation ratios, offering a comprehensive snapshot of the company's financial health and market performance. The data includes information on sales, earnings per share, profit margins, stock performance over different periods, and short interest.
Form 144 INTELLIA THERAPEUTICS For: 2 July By Investing.com
This article reports on a Form 144 filing for Intellia Therapeutics (NTLA) for July 2nd. Form 144 is a notice of the intent to sell restricted securities. The article provides the title, author and date of publication without further details on the filing itself.
Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
This document, titled "Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144," indicates that Intellia Therapeutics has issued a notice regarding the proposed sale of securities under Rule 144. Further details about the sale would be contained within the document itself.
[144] Intellia Therapeutics, Inc. SEC Filing
This SEC filing is a Form 144 Notice of Proposed Sale of Securities for Intellia Therapeutics, Inc. (NTLA). An individual plans to sell 4677 shares of common stock with an aggregate market value of $80631.48 as of July 2, 2026, which were acquired through Restricted Stock Units on January 1, 2026. The sale will be executed via Morgan Stanley Smith Barney LLC on NASDAQ.
Intellia Therapeutics (NTLA) Is Up 11.2% After Lonvo-z Phase 3 Progress And 2027 Launch Plans - Has The Bull Case Changed?
Intellia Therapeutics (NTLA) saw an 11.2% stock price increase following positive Phase 3 results for its ATTR therapy, Lonvo-z, and plans for a 2027 U.S. launch. This clinical progress is critical for the gene-editing company, which faces high short interest and concerns regarding valuation, funding needs, and commercial readiness. The success provides a clearer regulatory path and concrete timing for Lonvo-z, potentially easing development risk while investors remain aware of ongoing cash burn and potential dilution.
Intellia Therapeutics (NTLA) Is Up 11.2% After Lonvo-z Phase 3 Progress And 2027 Launch Plans - Has The Bull Case Changed?
Intellia Therapeutics (NTLA) shares surged by 11.2% following positive Phase 3 results for its gene-editing therapy, Lonvo-z, and plans for a U.S. launch in the first half of 2027. This clinical progress is significant given high short interest and concerns about valuation and funding. The company aims for U.S. regulatory approval and a sharper investment narrative, though risks like cash burn and commercialization hurdles remain.
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy
Intellia Therapeutics (NTLA) stock surged 35% overnight as retail investors anticipate the results of its Phase 3 Haelo trial for Lonvo-z, a gene-editing treatment for hereditary angioedema. This trial is significant as it marks the first late-stage test of an in-vivo CRISPR gene-editing treatment. The company has also seen recent positive regulatory developments with the FDA lifting clinical holds on two other Phase 3 trials for Nex-z, a treatment for transthyretin amyloidosis.
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Intellia Therapeutics (NASDAQ: NTLA) has seen its stock climb significantly this year due to strong clinical progress, particularly with its gene-editing candidate lonvo-z. Wall Street analysts predict the stock could rise another 57% based on its average price target, driven by lonvo-z's successful phase 3 trial and another promising late-stage asset, nex-z. However, the company faces substantial risks, including the commercial viability of its expensive gene-editing treatments and potential regulatory setbacks, making it a volatile investment suitable for those comfortable with high risk.
NTLA Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and events related to Intellia Therapeutics (NTLA), including stock movements, analyst opinions, and reports on its gene editing treatment, Lonvo-z. Key highlights include positive Phase 3 results for Lonvo-z, the stock's performance after these announcements, and market reactions to broader economic news like the U.S.-Iran peace agreement.
Intellia Therapeutics (NTLA) Stock Looks Overvalued On Sales Despite Strong Trial Progress
Intellia Therapeutics (NTLA) stock has rebounded recently, but its long-term performance and current valuation suggest it may be overvalued. Despite positive Phase 3 trial results for its gene-editing therapy lonvo z, the company's P/S ratio of 35.8x is significantly higher than the biotech industry average, indicating investors are paying a steep premium for future potential rather than current profits. The article concludes that today's rich sales multiple needs to be justified by strong revenue and margin growth, or the stock could face disappointment.
Price to earnings forward of Intellia Therapeutics, Inc. – DUS:38I
This article provides financial information for Intellia Therapeutics, Inc. (DUS:38I) on the Düsseldorf Stock Exchange. It specifically mentions "Price to earnings forward" as a key financial metric but does not provide the actual value. The content primarily lists navigation and platform features of TradingView, where this data would presumably be displayed.
Price to book forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA
This article provides a financial data point for Intellia Therapeutics, Inc. (NASDAQ: NTLA), specifically its "Price to book forward." It notes that the market for NTLA is currently closed and provides general information about the data source from TradingView. The page primarily serves as a placeholder for this specific financial metric.
Price to book forward of Intellia Therapeutics, Inc. – DUS:38I
The article provides a financial overview of Intellia Therapeutics, Inc. (38I) on the Dusseldorf Stock Exchange, specifically focusing on its Price to Book Forward metric. It notes that the market is currently closed with no trades recorded.
Enterprise value to revenue forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA
This article provides the enterprise value to forward revenue for Intellia Therapeutics, Inc. (NASDAQ: NTLA). It is a brief financial data point related to the biotechnology company. The content appears to be from a financial data platform like TradingView, showing stock market information for NTLA.
Enterprise value to revenue forward of Intellia Therapeutics, Inc. – DUS:38I
This article provides financial information for Intellia Therapeutics, Inc. (DUS:38I) on the Dusseldorf Stock Exchange. It specifically mentions the "Enterprise value to revenue forward" metric, indicating the company's financial valuation is being discussed, presumably for investors or market analysis.
Enterprise value to EBITDA forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA
This article provides a financial snapshot for Intellia Therapeutics, Inc. (NASDAQ: NTLA), specifically focusing on its enterprise value to EBITDA forward. It indicates the stock is listed on the Nasdaq Stock Market and provides a framework for financial analysis. The content is primarily a data placeholder from TradingView, offering a metric for further investment research.
Price to earnings forward of Intellia Therapeutics, Inc. – BOATS:NTLA
This article provides the "Price to earnings forward" metric for Intellia Therapeutics, Inc. (NTLA) under the Blue Ocean Alternative Trade System (BOATS). The financial data is sourced from ICE Data Services, FactSet Research Systems, and Quartr.
Certain Stock Options of Intellia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2026.
Certain stock options for Intellia Therapeutics, Inc. are under a lock-up agreement that concludes on June 28, 2026. This agreement, spanning 61 days from April 28, 2026, prevents company directors and executive officers from liquidating or hedging their common stock or related securities without underwriter consent.
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics
Levi & Korsinsky LLP has announced a class action lawsuit against Intellia Therapeutics, Inc. (NASDAQ: NTLA) on behalf of shareholders who suffered losses between July 30, 2024, and January 8, 2025. The lawsuit alleges securities fraud, claiming Intellia failed to disclose that demand for viral-based editing was decreasing, making their NTLA-3001 program inefficient. Investors are encouraged to learn about their rights to seek recovery.
Intellia Therapeutics, Inc. Actuals & Estimates (NASDAQ:NTLA)
Intellia Therapeutics, Inc. (NASDAQ: NTLA) stock is currently trading at $16.68, showing a 4.05% increase in the last 24 hours. Analysts forecast a wide price range for NTLA, with a maximum estimate of $95.00 and a minimum of $8.00. The company will release its next earnings report on July 30, 2026, with recent earnings per share at $-0.81, beating estimates, and revenue at $15.05 million, also exceeding expectations.
Intellia Therapeutics, Inc. Actuals & Estimates (BX:38I)
This article provides an overview of Intellia Therapeutics, Inc. (38I) stock performance, financial data, and analyst forecasts on TradingView. It includes details on the current stock price, market capitalization, earnings, revenue, and EBITDA, along with historical highs and lows. The piece also covers analyst price targets and technical analysis recommendations for potential investors.
Impressive Clinical Trial Data Drives Intellia Therapeutics Up 70% This Year
Intellia Therapeutics (NTLA) has seen its stock rise over 70% this year due to impressive Phase III clinical trial data for its lead product, lonvo-z, which treats hereditary angioedema. The company is transitioning towards commercialization with regulatory submissions underway and anticipates a market launch next year. Analysts predict a further 70% upside for the stock, driven by confidence in its CRISPR gene-editing technology and expanding pipeline.
StockWatch: Positive Phase III Data Sells Investors on Intellia
Intellia Therapeutics' shares surged after positive Phase III data for its gene-editing candidate, lonvoguran ziclumeran (lonvo-z), in hereditary angioedema (HAE). The therapy met primary and secondary endpoints, leading analysts to anticipate FDA approval and strong market adoption despite existing competition. CEO John Leonard states that lonvo-z could save lifetime healthcare resources for HAE patients, positioning it as a potentially cost-effective one-time treatment.
Intellia Therapeutics (NTLA) Is Up 29.4% After New Phase 3 Lonvo-z Data and FDA Filing
Intellia Therapeutics (NTLA) shares surged 29.4% following positive Phase 3 HAELO trial data for its CRISPR therapy, lonvo-z, targeting hereditary angioedema. The company also filed a rolling biologics license application with the FDA and published results in the New England Journal of Medicine, positioning lonvo-z as a potential one-time treatment. Despite the strong clinical data, risks remain regarding competition, long-term CRISPR safety concerns, payer pushback on pricing, and the need for further capital raising.
Intellia Therapeutics (NTLA) Stock Could Be 41.2% Undervalued After Phase 3 HAE Data
Intellia Therapeutics (NTLA) is drawing attention after releasing positive Phase 3 HAELO trial data for its CRISPR-based therapy lonvo-z in hereditary angioedema and submitting a rolling biologics license application to the FDA. Despite a recent 70.14% year-to-date share price increase, the stock is considered by some narratives to be 41.2% undervalued compared to an estimated fair value of $26.63, though its high P/S ratio indicates strong market optimism. Investors are encouraged to review the company's financials and risks to form their own stance regarding its future potential.
Intellia Therapeutics (NTLA) Sees 10.7% Surge in Stock Price
Intellia Therapeutics (NTLA) saw a significant stock price surge of 10.7% on June 17, 2026, driven by increased investor confidence in its CRISPR/Cas9 gene-editing technology. Despite a solid GF Score™ of 72, indicating strong growth prospects, the company's low profitability rank and a trend of insider selling transactions warrant careful consideration from investors.
NTLA Stock Climbs As Phase 3 CRISPR Data Turn Heads
Intellia Therapeutics Inc. (NTLA) stock surged by 10.24% following promising Phase 3 CRISPR gene-editing trial results for its drug lonvo-z, aimed at hereditary angioedema. The data, published in the New England Journal of Medicine and presented at EAACI 2026, showed significant attack reductions and quality-of-life improvements. Intellia is pursuing a rolling Biologics License Application with the FDA, targeting a U.S. launch in the first half of 2027, making NTLA a significant focus for traders despite its development-stage financials.
Intellia’s gene editor ‘keeps pace’ with Ionis in hereditary angioedema
Intellia Therapeutics' CRISPR-based gene editing therapy, lonvo-z, showed significant efficacy in a Phase 3 study for hereditary angioedema, reducing disease attack episodes by 89% and moderate/severe attacks by 91%. Analysts predict lonvo-z could challenge Ionis Pharmaceuticals' angioedema drug, Dawnzera, due to its "paradigm-shifting" one-time dosing profile. Intellia expects to complete its FDA submission in the second half of this year, with potential approval and launch in the first half of 2027.
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
Intellia Therapeutics (NTLA) shares surged 23.2% after announcing additional positive data from its phase III HAELO study for lonvo-z, an HAE gene-editing therapy. The latest data showed lonvo-z significantly reduced the monthly rates of HAE attacks, further demonstrating its potential for meaningful disease control. Intellia is pursuing FDA approval and plans a commercial launch in the first half of 2027.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) shares surged 23.2% after
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)
This article highlights recent analyst ratings for several healthcare companies. Wells Fargo maintained a Hold rating on Incyte (INCY), while TD Cowen and William Blair reiterated Buy ratings for Intellia Therapeutics (NTLA). Wells Fargo also maintained a Hold rating on Halozyme (HALO), with all three companies receiving a "Moderate Buy" consensus from analysts overall.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) shares surged 23.2% after reporting positive new data from its Phase III HAELO study for hereditary angioedema (HAE), with lonvo-z significantly reducing attack rates. Despite this jump, the company is still expected to post a quarterly loss, although with increased revenue. Investors are advised to monitor NTLA's future performance and earnings estimate revisions to determine if this strength will continue.
Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results
Intellia Therapeutics saw its share price jump 23% following positive Phase 3 results for its hereditary angioedema (HAE) treatment, Lonvo-Z. The drug achieved an 87% reduction in monthly attacks compared to placebo and demonstrated favorable safety, with 62% of patients being attack-free and therapy-free for six months. Intellia plans to launch Lonvo-Z in the first half of 2027 and has already submitted a biologics license application.
Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results
Intellia Therapeutics (NTLA) shares surged by 23.20% after reporting encouraging Phase 3 results for its hereditary angioedema (HAE) treatment candidate, Lonvo-Z. The study showed an 87% reduction in mean monthly HAE attacks, with 62% of patients achieving attack-free status, compared to a placebo group. Intellia plans to launch the treatment in the first half of 2027 and has submitted a rolling biologics license application to the FDA.
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9
Goldman Sachs has reiterated its Sell rating for Intellia Therapeutics (NTLA.US), keeping the target price at $9. This indicates a continued bearish outlook from the investment bank on the company's stock.
Intellia Therapeutics options trading jumps to 7,041 contracts By Investing.com
Intellia Therapeutics Inc.'s options trading volume significantly increased to 7,041 contracts on Monday morning, with call options representing the majority of the activity. The June 18, 2026 $13 and $14 call options saw substantial contract volumes. Shares of Intellia Therapeutics rose by 15.4% to $13.98 following this trading activity.
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
Intellia Therapeutics' gene-editing therapy, lonvo-z (previously NTLA-2002), has shown promising results in its Phase 3 HAELO trial for hereditary angioedema (HAE), demonstrating an 87% reduction in monthly HAE attacks compared to placebo. The data, presented at EAACI 2026 and published in The New England Journal of Medicine, highlighted the therapy's favorable safety profile and its potential to compete with existing treatments. Analysts view these findings as strengthening Intellia's case for regulatory approval, with a rolling BLA submission expected in the second half of 2026.
Intellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment
Intellia Therapeutics has released additional positive phase 3 data for its one-time gene-editing therapy, lonvoguran ziclumeran (lonvo-z), for hereditary angioedema (HAE). The results showed significant reductions in HAE attacks and improvements in quality of life, meeting secondary endpoints with statistical and clinical significance. The company anticipates a launch in the first half of 2027, positioning lonvo-z as a potential "paradigm-shifting" treatment due to its one-time administration compared to existing chronic therapies.
Why Is NTLA Stock Jumping 5% Premarket Today?
Intellia Therapeutics (NTLA) stock surged 5% premarket after releasing additional Phase 3 data for its CRISPR-based hereditary angioedema (HAE) treatment, Lonvo-z. The data showed an 89% reduction in attacks requiring rescue medication and significant quality-of-life improvements. The company has already begun its FDA filing and aims for a Q1 2027 launch, potentially making Lonvo-z the first approved in vivo gene-editing medicine.
Why Intellia Therapeutics (NTLA) Is Down 10.6% After Advancing Lonvo-z Toward FDA Review And Commercialization
Intellia Therapeutics (NTLA) recently reported positive Phase 3 results for its gene-editing therapy, lonvo-z, for hereditary angioedema and has initiated a rolling biologics license application with the FDA. Despite this significant progress towards potential commercialization, the company's stock fell by 10.6%. This drop highlights investor concerns about the concentrated nature of Intellia's late-stage pipeline and the inherent regulatory risks associated with gene-editing therapies.
Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound?
This article discusses the recent performance of Intellia Therapeutics (NTLA), noting a 7.9% decline since its last earnings report. The piece poses the question of whether the stock can rebound from this downturn.
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Intellia Therapeutics announced additional positive Phase 3 results for lonvoguran ziclumeran (lonvo-z), its CRISPR-based investigational treatment for hereditary angioedema (HAE). The data from the HAELO clinical trial, presented at EAACI 2026 and published in The New England Journal of Medicine, showed an 87% reduction in mean monthly HAE attacks and significant improvements in quality of life with a favorable safety profile. Intellia anticipates regulatory approval and a U.S. launch of lonvo-z in the first half of 2027.
Intellia Therapeutics Reports Additional Positive Phase 3 Results For Lonvoguran Ziclumeran (Lonvo-Z)
Intellia Therapeutics announced additional positive Phase 3 results for its drug Lonvoguran Ziclumeran (Lonvo-Z). The announcement indicates progress for the company in its clinical trials. The news is brief and provided by Refinitiv.
One-time CRISPR gene edit cuts HAE attacks by 87% in Phase 3 trial
Intellia Therapeutics reported additional positive Phase 3 HAELO data for its CRISPR gene-editing treatment, lonvo-z, showing an 87% reduction in mean monthly hereditary angioedema (HAE) attacks compared to placebo. The trial also demonstrated a significant improvement in quality of life for patients, with 62% of those treated remaining attack and therapy-free over a six-month period. Lonvo-z exhibited a favorable safety profile, and Intellia anticipates a U.S. launch in the first half of 2027 following ongoing regulatory submissions.
Exploring High Growth Tech Stocks In The US Market
This article identifies and discusses high-growth tech stocks in the US market, noting the market's recent decline but overall annual growth. It highlights key companies like LightPath Technologies, Intellia Therapeutics, and AppLovin, detailing their financial performance, growth potential, and strategic investments. The report emphasizes the importance of innovation, scalability, and strong fundamentals for these companies to thrive amidst market fluctuations.
Intellia (NTLA) director Muna Bhanji granted 9,200 RSUs and 13,300 options
Intellia Therapeutics (NTLA) director Muna Bhanji was granted 9,200 Restricted Stock Units (RSUs) and 13,300 stock options, as detailed in a recent Form 4 filing. The RSUs increase her direct common stock holdings to 36,403 shares, while the stock options have an exercise price of $12.89 and vest within one year or by the next annual stockholder meeting. This transaction represents an equity compensation award rather than a stock purchase.
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Goff Brian
This article is a Form 4 statement from Intellia Therapeutics, detailing changes in beneficial ownership of securities for Director Brian Goff, as required by the SEC.
Intellia (NTLA) director Georgia Keresty receives stock awards and options grant
Intellia Therapeutics director Georgia Keresty received equity compensation, including 9,200 restricted stock units (RSUs) and stock options for 13,300 shares at an exercise price of $12.89 per share. Following these grants, her direct holdings in common stock increased to 41,083 shares. The stock options are set to vest in full either on the first anniversary of the June 9, 2026 grant date or the company's next annual meeting of stockholders.
Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options
Intellia Therapeutics director Fred E. Cohen was granted 9,200 restricted stock units and a stock option for 13,300 shares, according to a recent SEC Form 4 filing. The RSUs increase his direct common stock holdings to 216,653 shares, while the stock option has an exercise price of $12.89 per share and vests fully on the earlier of one year from the June 9, 2026 grant date or the next annual stockholders' meeting, expiring on June 8, 2036. These transactions are compensation-related grants, not open-market trades.
